NanoViricides Seeks DRC Approval for Oral Ebola Treatment Trial

NanoViricides, Inc. (NYSE American: NNVC) has taken a significant step in combating the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo by applying to the country's regulatory agency for approval to initiate a Phase II clinical trial of its novel antiviral, NV-387 Oral Gummies. The company has partnered with Om Sai Clinical Research Private Limited as its contract research organization and has already positioned drug supplies within the DRC. NV-387 is an orally administered broad-spectrum antiviral that targets host-side mechanisms exploited by viruses to infect cells, a strategy NanoViricides believes could minimize the risk of viral resistance. This trial builds on the company's existing Phase II Mpox study in the DRC and addresses an outbreak that has resulted in over 930 deaths and nearly 2,400 confirmed cases since May 2024.

NanoViricides highlights the logistical advantages of NV-387's oral formulation over infusion-based therapies in resource-limited settings, potentially enabling broader access to treatment. If successful, NV-387 could pave the way for a broad-spectrum therapy effective against Ebola and other filoviruses. The company is a clinical-stage innovator leveraging its proprietary nanoviricide(TM) technology, based on intellectual property licensed from TheraCour Pharma, Inc. Its lead candidate, NV-387, is also being developed for respiratory viruses like RSV, COVID, and Influenza, as well as MPOX and Measles. Other pipeline assets include NV-HHV-1 for Shingles and two COVID-19 candidates: NV-CoV-2 and NV-CoV-2-R, the latter encapsulating remdesivir. NanoViricides' platform covers a wide range of viral diseases, from HIV and Hepatitis to Dengue and Ebola.

For more details, the full press release is available at https://ibn.fm/tmrCX. Investors can follow the latest updates on NNVC in the company's newsroom at https://ibn.fm/NNVC. This development underscores NanoViricides' commitment to addressing urgent global health threats with innovative antiviral strategies.